Researchers from New England Biolabs and Yale University have developed the first fully synthetic system for engineering bacteriophages targeting Pseudomonas aeruginosa, a major antibiotic-resistant bacterium. Published in PNAS, the method uses digital DNA sequences to build viruses from scratch, bypassing traditional challenges in phage modification. This innovation aims to accelerate therapies against global antibiotic resistance threats.
Bacteriophages, viruses that attack bacteria, have served as treatments for infections for over a century, but their use has surged amid rising antibiotic resistance. In a recent PNAS study, scientists from New England Biolabs (NEB) and Yale University introduced a breakthrough: a fully synthetic engineering system for phages that target Pseudomonas aeruginosa, an antibiotic-resistant pathogen posing worldwide risks.
The system leverages NEB's High-Complexity Golden Gate Assembly (HC-GGA) platform, enabling researchers to construct phages entirely from synthetic DNA fragments rather than natural virus samples. The team assembled a P. aeruginosa phage using 28 such fragments, then modified it by adding point mutations, insertions, deletions, swapping tail fiber genes to alter bacterial targets, and incorporating fluorescent markers for real-time infection tracking.
"Even in the best of cases, bacteriophage engineering has been extremely labor-intensive. Researchers spent entire careers developing processes to engineer specific model bacteriophages in host bacteria," said Andy Sikkema, co-first author and NEB research scientist. "This synthetic method offers technological leaps in simplicity, safety and speed, paving the way for biological discoveries and therapeutic development."
Unlike conventional techniques that require physical phage stocks and risky host bacteria, this approach builds the entire genome outside cells in a controlled manner, then activates it in safe lab strains. Golden Gate Assembly excels with short DNA segments, reducing errors and handling complex sequences like high GC content or repeats—issues that plague other methods.
The work stemmed from NEB-Yale collaboration, starting with optimizations on the E. coli phage T7 before tackling tougher targets. Related efforts include a November 2025 PNAS paper on synthetic Mycobacterium phages with the University of Pittsburgh's Hatfull Lab and Ansa Biotechnologies, and a December 2025 ACS study with Cornell University on T7-based E. coli biosensors for water safety.
"My lab builds 'weird hammers' and then looks for the right nails," noted Greg Lohman, NEB senior principal investigator and study co-author. "In this case, the phage therapy community told us, 'That's exactly the hammer we've been waiting for.'" This progress expands phage potential as precise antibiotics, addressing a critical health crisis without the limitations of natural viruses.
